Advertisement

Medical Oncology

, 33:78 | Cite as

Use of complementary and alternative medicine by patients with cancer: a cross-sectional study at different points of cancer care

  • J. Kleine Wortmann
  • A. Bremer
  • HT Eich
  • HP Kleine Wortmann
  • A. Schuster
  • J. Fühner
  • J. Büntzel
  • R. Muecke
  • FJ Prott
  • J. HuebnerEmail author
Original Paper

Abstract

Complementary and alternative medicine (CAM) is widely used by cancer patients. In order to learn more on the usage of CAM, its reasons and motifs as well as sources of information along the trajectory of treatment, we decided to evaluate the prevalence and predictors for the use of CAM by cancer patients while being under active treatment with chemo- or radiotherapy or in aftercare. We distributed a standardized questionnaire among patients attending a department of radio-oncology, an ambulance for oncology and offices of general practitioners (GPs). Five hundred and six patients took part. Most attributed cancer to stress and trauma (23.7 and 16.4 %) or genes (20.8 %). Forty-four percentage reported knowing a physician with competence in CAM, and in all settings, most patients named the GP. Fifty-one percentage admitted using CAM, 35 % informed the oncologist about using CAM, 56 % informed the GP, and 26 % did not inform any physician. Most often used CAM was vitamin D (17 %) and selenium (16 %). Most important goals were to strengthen the immune system (59 %) and become active (52 %). Most patients were satisfied with the CAM methods they used. Yet, with some methods, dissatisfaction was up to 30 %. The GP has an important function concerning CAM in oncology as most patients believe the GP to have best knowledge in CAM. In order to integrate complementary medicine into evidence-based medicine, physicians should be trained on how to communicate on CAM with the patient and with each other. Explaining cancer and cancer therapies in a way lay persons are able to understand may be helpful. Physicians should actively address patients’ needs of involvement not only in decision making, but also actively in the therapy.

Keywords

Complementary and alternative medicine Cancer Information needs 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

12032_2016_790_MOESM1_ESM.docx (34 kb)
Supplementary material 1 (DOCX 33.5 kb)

References

  1. 1.
    Eardley S, Bishop FL, Prescott P, et al. A systematic literature review of complementary and alternative medicine prevalence in EU. Forsch Komplementärmedizin Res Complement Med. 2012;19(s2):18–28.CrossRefGoogle Scholar
  2. 2.
    Molassiotis A, Fernadez-Ortega P, Pud D, et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005;16:655–63.CrossRefPubMedGoogle Scholar
  3. 3.
    Horneber M, Bueschel G, Dennert G, et al. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187–203.CrossRefPubMedGoogle Scholar
  4. 4.
    Micke O, Bruns F, Glatzel M, et al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med. 2009;1:22–30.Google Scholar
  5. 5.
    Huebner J, Micke O, Muecke R, et al. User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res. 2014;34:943–8.PubMedGoogle Scholar
  6. 6.
    Muenstedt K, Duetemeyer V, Huebner J. Patients’ considerations behind the use of methods from complementary and alternative medicine in the field of obstetrics in Germany. Arch Gynecol Obstet. 2013;288(3):527–30.CrossRefGoogle Scholar
  7. 7.
    Huebner J, Muenstedt K, Prott FJ, et al. Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care. 2014;9(1):60–3.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ott IM, Muenstedt K, Micke O, et al. Attitude of oncology/haematology nurses from German speaking countries towards complementary and alternative medicine. Trace Elem Electrolyt. 2015;32(2):74–80.CrossRefGoogle Scholar
  9. 9.
    Conrad C, Muenstedt K, Micke O, et al. Survey of members of the German society for palliative medicine regarding their attitudes towards complementary and alternative medicine for cancer patients. J Cancer Res Clin Oncol. 2014;140(7):1229–37.CrossRefPubMedGoogle Scholar
  10. 10.
    Trimborn A, Senf B, Muenstedt K, Buentzel J, et al. Attitude of employees of a university clinic to complementary and alternative medicine in oncology. Ann Oncol. 2013;24(10):2641–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Eschiti VS. Lesson from comparison of CAM use by women with female-specific cancers to others: it‘s time to focus on interaction risks with CAM therapies. Integrat Cancer Ther. 2007;6(4):313–44.CrossRefGoogle Scholar
  12. 12.
    Buessing A, Cysarz D, Edelhäuser F. Inanspruchnahme unterstützender komplementärmedizinischer Verfahren bei Tumorpatienten in der späteren Phase. Deutsche Zeitschrift für Onkologie. 2007;39:162–8.CrossRefGoogle Scholar
  13. 13.
    Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18(13):2505–14.PubMedGoogle Scholar
  14. 14.
    Paul M, Davey B, Senf B, et al. Patients with advanced cancer and their usage of complementary and alternative medicine. J Cancer Res Clin Oncol. 2013;130(9):1515–22.CrossRefGoogle Scholar
  15. 15.
    Zeller T, Muenstedt K, Stoll C, et al. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol. 2013;139:357–65.CrossRefPubMedGoogle Scholar
  16. 16.
    Klafke N, Eliott JA, Wittert GA, Olver IN. Prevalence and predictors of complementary and alternative medicine (CAM) use by men in Australian cancer outpatient services. Ann Oncol. 2012;23:1571–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Huebner J, Prott FJ, Micke O, Muecke R, Senf B, Dennert G, Muenstedt K. Online survey of cancer patients on complementary and alternative medicine. Oncol Res Treat. 2014;37:304–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Chrystal K, Allan S, Forgeson C, Issacs R. The use of complementary/alternative medicine by cancer patients in a New Zealand regional cancer treatment centre. N Z Med J. 2003;116(1168):U296.PubMedGoogle Scholar
  19. 19.
    Linke B, Liebl P, Marten D, Stoll C, Jung B, Wuensch P, Huebner J. Information concerning endocrine therapy and adherence of patients with breast and prostate cancer. Clin Oncol (R Coll Radiol). 2015;27(8):482–3.CrossRefGoogle Scholar
  20. 20.
    Vapiwala N, Mick R, Hampshire MK, Metz JM, DeNittis AS. Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer J. 2006;12(6):467–74.CrossRefPubMedGoogle Scholar
  21. 21.
    Loquai C, Dechent D, Garzarolli M, Kaatz M, Kaehler K, Kurschat P, et al. Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma. Med Oncol. 2016;33(5):52. doi: 10.1007/s12032-016-0764-6.
  22. 22.
    Loquai C, Dechent D, Garzarolli M, Kaatz M, Kaehler K, Kurschat P, et al. Interactions from complementary and alternative medicine in patients with melanoma-a survey of 1097 patients. Submitt.Google Scholar
  23. 23.
    Huebner J, Muenstedt K, Muecke R, Micke O, Stoll C, Kleeberg UR, Buentzel J, Dennert G. Prott FJ counseling cancer patients on complementary and alternative medicine. Strahlenther Onkol. 2013;189(8):613–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • J. Kleine Wortmann
    • 1
  • A. Bremer
    • 2
  • HT Eich
    • 3
  • HP Kleine Wortmann
    • 4
  • A. Schuster
    • 5
  • J. Fühner
    • 6
  • J. Büntzel
    • 7
  • R. Muecke
    • 8
  • FJ Prott
    • 9
  • J. Huebner
    • 1
    Email author
  1. 1.Working Group Integrative Oncology, Dr. Senckenberg Chronomedical InstituteJ.W. Goethe UniversityFrankfurtGermany
  2. 2.MVZ Media VitaMünsterGermany
  3. 3.Department of RadiooncologyUniversity Medicine MuensterMünsterGermany
  4. 4.GemeinschaftspraxisMünsterGermany
  5. 5.Practice Auf der Geist MünsterMünsterGermany
  6. 6.GemeinschaftspraxisMünsterGermany
  7. 7.Department of OtorhinolaryngologyHospital NordhausenNordhausenGermany
  8. 8.Department of Radiotherapy and Radiation OncologyRuhr UniversityBochumGermany
  9. 9.Department of RadiooncologyRNS Praxisgemeinschaft GbRWiesbadenGermany

Personalised recommendations